Skip to main content
SpringerLink
Log in

Long-term persistence of symptomatic effect of selegiline in parkinson’s disease, a two-months placebo-controlled withdrawal study

  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary

Following a two-months of placebo-controlled withdrawal, the MAO-B inhibitor selegiline was found to maintain a long term significant mild to moderate symptomatic effect on bradykinesia and tremor at rest in nine patients with Parkinson’s disease (stage II and III of H⇐p;Y), whose functional impairment had also required a dopaminergic therapy with low-dose bromocriptine. Both motor signs found worsened during the wash-out showed a full recovery to pre-withdrawal condition within two months after reinstitution of the drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Calzetti S, Negrotti A, Cassio A (1995) L-Deprenyl as an adjunct to low-dose bromocriptine in early Parkinson’s disease: a short-term, double-blind, and prospective follow-up study. Clin Neuropharmacol 3: 250–257

    Article  Google Scholar 

  • Koller WC (1996) Selegiline monotherapy in the treatment of Parkinson’s disease. Neurology 47 [Suppl 3]: 196–199

    Google Scholar 

  • Myllyla VV, Sotaniemi K, Mäki-Ikola O, Rinne UK, Heinonen EH (1996) Role of selegiline in combination therapy of Parkinson’s disease. Neurology 47 [Suppl 3]: 200–209

    Google Scholar 

  • Olanow CW, Hauser RA, Ganger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J (1995) The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 38: 771–777

    Article  PubMed  CAS  Google Scholar 

  • Pålhagen S, Heinonen EH, Hagglund J, Kaugesaar T, Kontants H, Mäki-Ikola O, Palm R, Turunen J, the Swedish Parkinson Study Group (1998) Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 51: 520–525

    PubMed  Google Scholar 

  • The Parkinson’s Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Neurologia, Università di Parma, Parma, Italy

    A. Negrotti, G. Bizzarri & S. Calzetti

  2. Istituto di Neurologia, Strada del Quartiere, 4, I-43100, Parma, Italy

    S. Calzetti

Authors
  1. A. Negrotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Bizzarri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Calzetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Negrotti, A., Bizzarri, G. & Calzetti, S. Long-term persistence of symptomatic effect of selegiline in parkinson’s disease, a two-months placebo-controlled withdrawal study. J Neural Transm 108, 215–219 (2001). https://doi.org/10.1007/s007020170089

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s007020170089

Keywords

Search

Navigation